264 related articles for article (PubMed ID: 27537525)
1. Bcl-xL is an oncogenic driver in colorectal cancer.
Scherr AL; Gdynia G; Salou M; Radhakrishnan P; Duglova K; Heller A; Keim S; Kautz N; Jassowicz A; Elssner C; He YW; Jaeger D; Heikenwalder M; Schneider M; Weber A; Roth W; Schulze-Bergkamen H; Koehler BC
Cell Death Dis; 2016 Aug; 7(8):e2342. PubMed ID: 27537525
[TBL] [Abstract][Full Text] [Related]
2. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
[TBL] [Abstract][Full Text] [Related]
3. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
Hari Y; Harashima N; Tajima Y; Harada M
Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
[TBL] [Abstract][Full Text] [Related]
4. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells.
Lee SJ; Park HJ; Kim YH; Kim BY; Jin HS; Kim HJ; Han JH; Yim H; Jeong SY
Int J Mol Med; 2012 Aug; 30(2):443-50. PubMed ID: 22664653
[TBL] [Abstract][Full Text] [Related]
6. Hypertonicity-imposed BCL-XL addiction primes colorectal cancer cells for death.
Heimer S; Knoll G; Steixner C; Calance DN; Trinh DT; Ehrenschwender M
Cancer Lett; 2018 Oct; 435():23-31. PubMed ID: 30075205
[TBL] [Abstract][Full Text] [Related]
7. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL.
Yosef R; Pilpel N; Tokarsky-Amiel R; Biran A; Ovadya Y; Cohen S; Vadai E; Dassa L; Shahar E; Condiotti R; Ben-Porath I; Krizhanovsky V
Nat Commun; 2016 Apr; 7():11190. PubMed ID: 27048913
[TBL] [Abstract][Full Text] [Related]
8. ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer.
Kim EY; Jung JY; Kim A; Chang YS; Kim SK
Neoplasia; 2017 Apr; 19(4):354-363. PubMed ID: 28319809
[TBL] [Abstract][Full Text] [Related]
9. Pan-Bcl-2 inhibitor Obatoclax is a potent late stage autophagy inhibitor in colorectal cancer cells independent of canonical autophagy signaling.
Koehler BC; Jassowicz A; Scherr AL; Lorenz S; Radhakrishnan P; Kautz N; Elssner C; Weiss J; Jaeger D; Schneider M; Schulze-Bergkamen H
BMC Cancer; 2015 Nov; 15():919. PubMed ID: 26585594
[TBL] [Abstract][Full Text] [Related]
10. The apoptosis inhibitor Bcl-xL controls breast cancer cell migration through mitochondria-dependent reactive oxygen species production.
Bessou M; Lopez J; Gadet R; Deygas M; Popgeorgiev N; Poncet D; Nougarède A; Billard P; Mikaelian I; Gonzalo P; Rimokh R; Gillet G
Oncogene; 2020 Apr; 39(15):3056-3074. PubMed ID: 32066881
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
Lieber J; Kirchner B; Eicher C; Warmann SW; Seitz G; Fuchs J; Armeanu-Ebinger S
Pediatr Blood Cancer; 2010 Dec; 55(6):1089-95. PubMed ID: 20680965
[TBL] [Abstract][Full Text] [Related]
12. The Bcl-2/Bcl-XL inhibitor ABT-737 promotes death of retinoblastoma cancer cells.
Allaman-Pillet N; Oberson A; Munier F; Schorderet DF
Ophthalmic Genet; 2013; 34(1-2):1-13. PubMed ID: 21955141
[TBL] [Abstract][Full Text] [Related]
13. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Chen S; Dai Y; Harada H; Dent P; Grant S
Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
[TBL] [Abstract][Full Text] [Related]
14. Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer.
Zeuner A; Francescangeli F; Contavalli P; Zapparelli G; Apuzzo T; Eramo A; Baiocchi M; De Angelis ML; Biffoni M; Sette G; Todaro M; Stassi G; De Maria R
Cell Death Differ; 2014 Dec; 21(12):1877-88. PubMed ID: 25034785
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Bcl-xL prevents pro-death actions of ΔN-Bcl-xL at the mitochondrial inner membrane during glutamate excitotoxicity.
Park HA; Licznerski P; Mnatsakanyan N; Niu Y; Sacchetti S; Wu J; Polster BM; Alavian KN; Jonas EA
Cell Death Differ; 2017 Nov; 24(11):1963-1974. PubMed ID: 28777375
[TBL] [Abstract][Full Text] [Related]
16. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
17. Targeting ERK1/2-bim signaling cascades by BH3-mimetic ABT-737 as an alternative therapeutic strategy for oral cancer.
Shin JA; Kim LH; Lee SJ; Jeong JH; Jung JY; Lee HN; Hong IS; Cho SD
Oncotarget; 2015 Nov; 6(34):35667-83. PubMed ID: 26447615
[TBL] [Abstract][Full Text] [Related]
18. A brewing understanding of the regulation of Bax function by Bcl-xL and Bcl-2.
Renault TT; Dejean LM; Manon S
Mech Ageing Dev; 2017 Jan; 161(Pt B):201-210. PubMed ID: 27112371
[TBL] [Abstract][Full Text] [Related]
19. Bcl-xL controls a switch between cell death modes during mitotic arrest.
Bah N; Maillet L; Ryan J; Dubreil S; Gautier F; Letai A; Juin P; Barillé-Nion S
Cell Death Dis; 2014 Jun; 5(6):e1291. PubMed ID: 24922075
[TBL] [Abstract][Full Text] [Related]
20. Bcl-xL stimulates Bax relocation to mitochondria and primes cells to ABT-737.
Renault TT; Teijido O; Missire F; Ganesan YT; Velours G; Arokium H; Beaumatin F; Llanos R; Athané A; Camougrand N; Priault M; Antonsson B; Dejean LM; Manon S
Int J Biochem Cell Biol; 2015 Jul; 64():136-46. PubMed ID: 25862283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]